SorafiRel™ (Sorafenib) - LifeSciences
- AzatiRel® (Azacitidine)
- BortiRel® (Bortezomib)
- ErlotiRel® (Erlotinib)
- ImatiRel® (Imatinib)
- Isabis® (Sodium hyaluronate)
- LeuproRel® (Leuprolide)
- ReliCitabine® (Capecitabine)
- ReliDomide® (Lenalidomide)
- ReliTrexed® (Pemetrexed)
- SynoLife™ / SynoLife One™ (Hyaluronate Injection)
- TemoRel® (Temozolomide)
- TerliRel® (Terlipressin)
- SorafiRel™ (Sorafenib)
Business Pharmaceuticals SorafiRel
SorafiRel™ (Sorafenib) is a multikinase inhibitor. It works by slowing down the rate of growth of cancer cells and cutting off the blood supply that helps cancer cells grow.
Sorafenib is indicated for the treatment of patients, with unresectable hepatocellular carcinoma (HCC) and advanced renal cell carcinoma (RCC). Sorafenib is also indicated for the treatment of patients, with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine treatment.
SorafiRel™ (Sorafenib) tablets for oral administration are available in dosage strengths equivalent to 200 mg.